Literature DB >> 19654265

Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a.

Baskaran Thyagarajan1, Natalia Krivitskaya, Joseph G Potian, Kormakur Hognason, Carmen C Garcia, Joseph J McArdle.   

Abstract

Botulinum neurotoxin A (BoNT/A), the most toxic, naturally occurring protein, cleaves synapse-associated protein of 25 kDa and inhibits acetylcholine release from motor nerve endings (MNEs). This leads to paralysis of skeletal muscles. Our study demonstrates that capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of BoNT/A. Bilateral injection of BoNT/A near the innervation of the Extensor digitorum longus (EDL) muscle of adult Swiss-Webster mice inhibited the toe spread reflex (TSR). However, when capsaicin was coinjected bilaterally, or injected 4 or 8 h before injecting BoNT/A, the TSR remained normal. In animals that were pretreated with capsazepine, capsaicin failed to protect against the neuroparalytic effects of BoNT/A. In vivo analyses demonstrated that capsaicin protected muscle functions and electromygraphic activity from the incapacitating effects of BoNT/A. The twitch response to nerve stimulation was greater for EDL preparations isolated from mice injected with capsaicin before BoNT/A. Capsaicin pretreatment also prevented the inhibitory effects of BoNT/A on end-plate currents. Furthermore, pretreatment of Neuro 2a cells with capsaicin significantly preserved labeling of synaptic vesicles by FM 1-43. This protective effect of capsaicin was observed only in the presence of extracellular Ca(2+) and was inhibited by capsazepine. Immunohistochemistry demonstrated that MNEs express transient receptor potential protein of the vanilloid subfamily, TRPV1, the capsaicin receptor. Capsaicin pretreatment, in vitro, reduced nerve stimulation or KCl-induced uptake of BoNT/A into motor nerve endings and cholinergic Neuro 2a cells. These data demonstrate that capsaicin interacts with TRPV1 receptors on MNEs to reduce BoNT/A uptake via a Ca(2+)-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654265      PMCID: PMC2775269          DOI: 10.1124/jpet.109.156901

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

Review 1.  The cosmetic uses of Botulinum toxin type A.

Authors:  A V Benedetto
Journal:  Int J Dermatol       Date:  1999-09       Impact factor: 2.736

2.  Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart.

Authors:  Masato Tsuboi; Yasuyuki Furukawa; Fumio Kurogouchi; Koichi Nakajima; Masamichi Hirose; Shigetoshi Chiba
Journal:  Jpn J Pharmacol       Date:  2002-07

3.  Identification of an ion channel-forming motif in the primary structure of tetanus and botulinum neurotoxins.

Authors:  M S Montal; R Blewitt; J M Tomich; M Montal
Journal:  FEBS Lett       Date:  1992-11-16       Impact factor: 4.124

4.  The origin, structure, and pharmacological activity of botulinum toxin.

Authors:  L L Simpson
Journal:  Pharmacol Rev       Date:  1981-09       Impact factor: 25.468

5.  Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum.

Authors:  C R Mantyh; T N Pappas; J A Lapp; M K Washington; L M Neville; J R Ghilardi; S D Rogers; P W Mantyh; S R Vigna
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

6.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.

Authors:  J Blasi; E R Chapman; E Link; T Binz; S Yamasaki; P De Camilli; T C Südhof; H Niemann; R Jahn
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

7.  Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena.

Authors:  J J McArdle; D Angaut-Petit; A Mallart; R Bournaud; L Faille; J L Brigant
Journal:  J Neurosci Methods       Date:  1981-08       Impact factor: 2.390

8.  Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.

Authors:  S Kalandakanond; J A Coffield
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

9.  Development of botulinum toxin therapy.

Authors:  Alan B Scott
Journal:  Dermatol Clin       Date:  2004-04       Impact factor: 3.478

10.  Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I.

Authors:  Brian C Yowler; Richard D Kensinger; Cara-Lynne Schengrund
Journal:  J Biol Chem       Date:  2002-06-27       Impact factor: 5.157

View more
  9 in total

1.  Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Authors:  Mengfei Ho; Li-Hsin Chang; Melissa Pires-Alves; Baskaran Thyagarajan; Jordan E Bloom; Zhengrong Gu; Karla K Aberle; Sasha A Teymorian; Yuka Bannai; Steven C Johnson; Joseph J McArdle; Brenda A Wilson
Journal:  Protein Eng Des Sel       Date:  2010-11-04       Impact factor: 1.650

2.  Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Carmen C Garcia; Kormakur Hognason; Katerina Capková; Scott T Moe; Alan R Jacobson; Kim D Janda; Joseph J McArdle
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

3.  Capsaicin modulates acetylcholine release at the myoneural junction.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Padmamalini Baskaran; Joseph J McArdle
Journal:  Eur J Pharmacol       Date:  2014-10-23       Impact factor: 4.432

4.  Role of membrane cholesterol in spontaneous exocytosis at frog neuromuscular synapses: reactive oxygen species-calcium interplay.

Authors:  Alexey M Petrov; Anastasiya A Yakovleva; Andrey L Zefirov
Journal:  J Physiol       Date:  2014-10-17       Impact factor: 5.182

5.  Perturbation to Cholesterol at the Neuromuscular Junction Confers Botulinum Neurotoxin A Sensitivity to Neonatal Mice.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Joseph J McArdle; Padmamalini Baskaran
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

6.  Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.

Authors:  Padmamalini Baskaran; Teresa E Lehmann; Elena Topchiy; Nagarajan Thirunavukkarasu; Shuowei Cai; Bal Ram Singh; Sharad Deshpande; Baskaran Thyagarajan
Journal:  Toxicon       Date:  2013-06-25       Impact factor: 3.033

7.  Capsaicin and N-arachidonoyl-dopamine (NADA) decrease tension by activating both cannabinoid and vanilloid receptors in fast skeletal muscle fibers of the frog.

Authors:  Xóchitl Trujillo; Mónica Ortiz-Mesina; Tannia Uribe; Elena Castro; Rocío Montoya-Pérez; Zorayda Urzúa; Alfredo Feria-Velasco; Miguel Huerta
Journal:  J Membr Biol       Date:  2014-09-17       Impact factor: 1.843

8.  Sensing the deadliest toxin: technologies for botulinum neurotoxin detection.

Authors:  Petr Capek; Tobin J Dickerson
Journal:  Toxins (Basel)       Date:  2010-01-07       Impact factor: 4.546

9.  Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A.

Authors:  Xiaqing Li; Julie A Coffield
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.